Trials that use: One-sided testing
New to this method? Read the tutorial →
21 results
- APPRAISE-2Independent statistical analysis of APPRAISE-2, the randomized phase 3 trial of apixaban versus placebo in acute coronary syndrome, including time-to-event endpoints, Cox models, hazard ratios, confidence intervals, p-values, and safety results.
- ARASENSIndependent statistical analysis of ARASENS, the randomized phase 3 trial of darolutamide plus standard androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer, including time-to-event methodology, reported hazard ratios, confidence intervals,…
- CARMELINAIndependent statistical analysis of CARMELINA (NCT01897532), a randomized phase 4 trial of linagliptin versus placebo in patients with type 2 diabetes mellitus, including time-to-event methodology, non-inferiority testing, cardiovascular and renal endpoints, safety,…
- ENDEAVORIndependent statistical analysis of the ENDEAVOR phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma, including progression-free survival, overall survival, response, safety, and statistical methodology.
- GRIPHONIndependent statistical analysis of the GRIPHON phase 3 trial of selexipag in pulmonary arterial hypertension, covering its randomized time-to-event endpoint, secondary analyses, statistical methods, confidence intervals, and interpretation.
- ICARIA-MMIndependent statistical analysis of the phase 3 ICARIA-MM trial comparing isatuximab, pomalidomide, and dexamethasone with pomalidomide and dexamethasone in refractory or relapsed and refractory multiple myeloma.
- IMvigor130Independent statistical analysis of IMvigor130, a randomized phase 3 trial of atezolizumab with platinum-based chemotherapy or as monotherapy in untreated locally advanced or metastatic urothelial carcinoma.
- KEYNOTE-177Independent statistical analysis of KEYNOTE-177, the randomized phase 3 trial of pembrolizumab versus standard of care in participants with MSI-H or dMMR stage IV colorectal carcinoma, covering PFS, overall survival, response, statistical…
- KEYNOTE-240Independent statistical analysis of KEYNOTE-240, a randomized phase 3 trial of pembrolizumab plus best supportive care versus placebo plus best supportive care in previously systemically treated advanced hepatocellular carcinoma.
- KEYNOTE-564Independent statistical analysis of KEYNOTE-564, a randomized phase 3 trial of pembrolizumab versus placebo in the adjuvant treatment of renal cell carcinoma after nephrectomy, including disease-free survival, trial design, statistical methodology, and…
- KEYNOTE-598Independent statistical analysis of KEYNOTE-598, a randomized phase 3 trial of pembrolizumab with ipilimumab versus pembrolizumab with placebo in untreated metastatic non-small cell lung cancer. Includes overall survival, progression-free survival, response, quality…
- KEYNOTE-811Independent statistical analysis of KEYNOTE-811, a randomized phase 3 trial of pembrolizumab plus trastuzumab and chemotherapy versus standard of care in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
- LEADERComplete statistical analysis of the LEADER phase 3 trial of liraglutide versus placebo in type 2 diabetes, including trial design, cardiovascular time-to-event endpoints, Cox regression, non-inferiority and superiority testing, secondary outcomes, safety,…
- MONARCH 2Independent statistical analysis of the MONARCH 2 phase 3 trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant, including trial design, progression-free survival, statistical methodology, interpretation, limitations, and safety.
- ODYSSEY OUTCOMESComplete statistical analysis of ODYSSEY OUTCOMES, the randomized phase 3 trial of alirocumab versus placebo after acute coronary syndrome, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, safety, and statistical interpretation.
- PEARLSIndependent statistical analysis of the PEARLS phase 3 trial of pembrolizumab versus placebo after resection in non-small cell lung cancer, including disease-free survival, Cox regression, hazard ratios, confidence intervals, one-sided testing, and…
- RESORCEIndependent statistical analysis of the phase 3 RESORCE trial of regorafenib versus placebo in hepatocellular carcinoma, including overall survival, time to progression, progression-free survival, tumor response, statistical methodology, and interpretation.
- RTOG 0617Independent statistical analysis of RTOG 0617, evaluating radiation therapy dose and cetuximab with chemotherapy in newly diagnosed unresectable stage III non-small cell lung cancer, with emphasis on survival, competing risks, safety, and…
- RTOG 0825Independent statistical analysis of RTOG 0825, a randomized phase 3 trial of temozolomide and radiation therapy with or without bevacizumab in patients with newly diagnosed glioblastoma.
- SWOG S0777Independent statistical analysis of SWOG S0777 (NCT00644228), a randomized phase 3 trial of lenalidomide and dexamethasone with or without bortezomib in previously untreated multiple myeloma.
- VISIONIndependent statistical analysis of the VISION phase 3 trial of 177Lu-PSMA-617 plus best supportive/best standard of care in metastatic castrate-resistant prostate cancer, including randomized design, time-to-event endpoints, hazard ratios, response analyses, safety,…